『壹』 求南京微創醫學科技有限公司在江寧區的工廠地址
南京微創醫學科技有限公司（南京）
公司地址：江蘇省南京市高新開發區高科三路10號
郵編：210061
『貳』 南京微創醫學科技有限公司 怎麼樣
聽說還行，還是自己看看
『叄』 江蘇省微納生物醫療器械設計與製造重點實驗室的發展歷程
江蘇省微納生物醫療器械設計與製造重點實驗室現有教授5人、副教授4人、研究生近100名，擁有各種先進的微細加工系統和分析測試系統。實驗室先後完成了國家973前期預研項目、自然科學基金和863計劃等數十項縱向及大量橫向科研項目。獲得了江蘇省科技進步一等獎一項、江蘇省科技進步二等獎、三等獎多項，取得了良好的社會、經濟效益。
江蘇省微納生物醫療器械設計與製造重點實驗室位於東南大學九龍湖校區機械樓二樓，已建成實驗用房1000平米，其中建成150平米醫用萬級超凈室和180平米恆溫恆濕超凈室；同時在共建單位南京微創醫學科技有限公司建有實驗與檢測場地300平米。
實驗室的建設和運行管理實行東南大學直接領導下的主任負責制。管理委員會成員由江蘇省科技廳、東南大學和南京微創科學技術有限公司有關人員組成。實驗室主任是最高行政和業務負責人，組織重大項目的申請與實施，制定實驗室的發展規劃，由東南大學聘任，任期四年。
自2003至2008年間，總共完成並承擔國家863項目、國家973預研項目、國家自然科學基金重點項目、國家自然科學基金項目十餘項，並與美國加州伯克利分校等國內外多家科研單位以及相關企業建立了長期合作關系。
實驗室主任為易紅教授，副主任為陳雲飛教授與倪中華教授。
『肆』 親人得了膽管癌，梗阻性黃疸，想用南京微創醫學科技股份有限公司的膽道支架產品
國產支架可以用，只是相比進口支架在質量上還有待更大規模的使用報告，才能證明其效果。如果是自己的親人，在當前階段，還是優先用進口支架最踏實。
『伍』 南京生物醫葯谷的企業簡介
南京生物醫葯谷已經聚集生物醫葯類企業142家，涵蓋生物制葯、化學制葯、醫療器械、中醫葯、研發服務外包等多個門類，其對應代表企業分別有綠葉思科、葯石葯物、微創醫學、海昌中葯、金斯康科技等。這些企業自身「造血」功能強勁，盈利能力良好，其中銷售過億元企業5家，過億元產品2個。這些各領風騷的生物醫葯產業集群，不僅構築起了生物醫葯谷產業的新高地，也使得園區成為省內生物醫葯研發和孵化實力最強、數量最為集中區域之一。
『陸』 請大家幫忙翻譯這段話 謝謝
Introced on behalf of the enterprise
I, on behalf of the enterprise-based R & D outsourcing
Nanjing Chuanbo Biotechnology Co., Ltd. in August 2003 incorporated in the high-tech zones, with a registered capital of 12,000,000 yuan, is a Ph.D. from abroad and domestic scientists co-founder of the biotechnology business. Chuanbo to have a biological foreign experts and overseas students as the main body and doctorate or master's degrees composition of the technical backbone of the team. The company is committed to research and development of anti-antibody protein phosphorylation, after 3 years of research and development, has succeeded in building a development of the anti-protein phosphorylation antibody technology platform, has developed 17 kinds of cell signaling pathway in the 638 kinds of anti-phosphorylation Protein antibodies, 73 of which for the first time on the international success of the development of the antibody procts, procts have been sold in the United States, Canada, Britain, France, Germany and Japan more than 20 countries. Annual output value reached 125 million. Science and Technology Development Zone Company and established a joint venture center "of the Nanjing International Antibody Engineering Research Center," the company for long-term development strategy that antibody drug research platform for international cooperation.
Second, the proction of medical equipment on behalf of the enterprise
Minimally invasive Nanjing Medical Technology Co., Ltd. specializes in interventional stent lumen, a one-time sterile digestive endoscope, and so on endoscopic biopsy forceps the annex to the research and development of procts and proction sales. Own more than 10 patents, the Ministry of Health is "100 10-year plan to" bear the unit, China is the birthplace of the one-time biopsy forceps. The company has 1500 in line with the GMP requirements of 10,000 square meters clean workshop, is currently the only shop in the clean proction of the stent business. Company sales in 2007 amounted to 100,000,000 yuan.
Third, medicine, health procts on behalf of the proction-oriented enterprises
Kang Hae Medicine Co., Ltd. Nanjing (formerly Nanking Zhenzhong Biological Engineering Co., Ltd.), the main proct is Lentinan Nanjing in a row to support the eight years of their own intellectual property rights of high-tech procts. The procts have more than 80% of the domestic market, with an annual output capacity of 650,000, the output value reached 80,000,000 yuan. The other two companies - taxol liposomes and selegiline hydrochloride in the next two years will create a proction value of 50,000,000 yuan. The company is "Lentinan freeze-dried powder", "amifostine injection", "paclitaxel liposome components" has been an international PCT patent applications and has the United States, Japan, Russia, India, Thailand, the European Union Multi-national patent applications.
High-tech Zone of bioengineering and medicine instry with the times, the instry continues to prosper and grow in 2010 and bio-medical engineering science and technology park planning area will be 5.2 square kilometers, 200 enterprises to join in annual sales 20,000,000,000 yuan . Chinese medicine and bio-technology park for a leading innovation-driven, and increase input in research funding, to foster a number of market competitiveness and self-development capacity of the backbone of the new entity; at the same time establish and improve the research and development, pilot proction technology platform. With mice research advantage of the resources of the library resources, biological targeting information technology, biomedical engineering, gene therapy technology to carry out instrialization of research work, at home and abroad to introce genetic engineering-related fields of research and development institutions to further biomedical park in Nanjing to play the "three drug "Model Base of new drugs and the role of R & D base, to build a unique national biomedical research base.
Focus on the future development of the field
① biological information technology, bio-chip technology, biomedical engineering, gene therapy, cell therapy, such as the instrialization of research. Focus on the development of bio-informatics research and development platform, biological diagnostic chips, cellular immune therapy drugs, monoclonal antibody diagnostic reagents, genetic engineering drugs and vaccines and other procts.
② Chinese medicine and natural medicine quality standard certification technology; ingredient extraction, separation, purification, micro technology; active ingredients of Chinese medicine screening, the study of lead compounds, controlled-release technology of proprietary Chinese medicines, transdermal absorption of technology and targeted drug delivery technology And the development of Chinese medicine capsules, effervescent tablets, injections, pills, tablets, oral solution, and other new agents.
③ priority to the development of pharmaceutical chemical release, controlled release, targeted drug delivery technology and other modern technology. For cardiovascular disease, cancer, diabetes, autoimmune disease, kidney disease and hepatitis, multiple illnesses, development, with the introction of advanced technology at home and abroad of new drugs.
『柒』 想問下 你同學在南京微創醫學科技工作從事的是什麼崗位的工作啊
研發工作